The CIHR Canadian HIV Trials Network (CTN) is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others that facilitate HIV clinical trials of the highest scientific and ethical standards.
Established in 1990 as a cornerstone of the federal AIDS Strategy, the CTN is funded by the Canadian Institutes of Health Research (CIHR), and jointly sponsored by the University of British Columbia and St. Paul’s Hospital (Providence Health Care) in Vancouver.
Over 300 trials reviewed
Implemented 170 trials of HIV therapies
Over 10,000 participants
Funded 136 CTN Postdoctoral Fellowships
The CTN is a Canada-wide partnership of researchers, caregivers, governments, health advocates, the innovative pharmaceutical and biotechnology industry, and people living with HIV who are committed to developing treatments, preventions and a cure for HIV and related health conditions, through the conduct of scientifically sound and ethical trials. The CTN is committed to maximizing the impact of research and ultimately improving the health of Canadians by applying knowledge gained through research at home and abroad into applications and practice.
The CTN continues to facilitate high-quality, investigator-driven clinical trials and innovative clinical research, while engaging with knowledge-brokers and community in both official languages, and sharing resources and expertise among researchers, clinical trial sites, and institutions.
The CTN’s vision is translated into an actionable research agenda via the activities of our Research Cores. Each Core has its own priorities, but linkages and cross-cutting themes enable our researchers to maximize their collective capacity, addressing research priorities for both the Canadian HIV population and similarly affected populations abroad.
The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…
Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….
CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.
Hi everyone! My name is Sonia, and I’m one of the Communications and Knowledge Translation Interns working with the CTN this summer.